CNTEClinical Trialsbusinesswire

ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients

Sentiment:Positive (80)

Summary

SAN DIEGO--(BUSINESS WIRE)-- #5hmC--ClearNote Health announced initiation of patient enrollment for a landmark UK clinical study utilizing its Avantect Pancreatic Cancer Test.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on June 16, 2025 by businesswire

    ClearNote Health Avantect® Pancreatic Cancer Test Enters Patient Enrollment Phase of Groundbreaking UK Study Targeting High-Risk Patients | CNTE Stock News | Candlesense